Skip to main content
. Author manuscript; available in PMC: 2019 Dec 27.
Published in final edited form as: Clin Cancer Res. 2008 Jul 1;14(13):4146–4153. doi: 10.1158/1078-0432.CCR-07-4536

Fig. 3.

Fig. 3.

A, average calibrated fluorescence of CAVEGF in PC-3 s.c. tumors pretreated with i.v. injection of 0 mg (n = 7), 0.3 mg (n = 4), and 1mg (n = 10) of Avastin 24 h before PDT. Hyperspectral fluorescence images were acquired at 24 h following PDT. Bars, SE. *, P < 0.05, statistically significant difference compared with the tumors that were not pretreated with Avastin. B, average calibrated fluorescence of CAVEGF in PC-3 s.c. tumors pretreated with i.v. injection of 1 mg bovine serum albumin (n = 6) or 1mg MLN591antibody (n = 4) 24 h before PDT. Hyperspectral fluorescence images were acquired at 24 h following PDT. Bars, SE. C, average calibrated fluorescence of MLN591-Alexa Fluor 680 conjugate in nontreated and PDT-treated PC-3 s.c. tumors 24 h following PDT. Average of five tumors per group; bars, SE.